Abstract Lower back pain is one of the most prevalent musculoskeletal conditions in the developed world and accounts for significant health services use. The American College of Physicians and the American Pain Society have published a joint clinical guideline that recommends providing patients with information on prognosis and selfmanagement, the use of medications with proven benefits and, for those who do not improve, consideration be given to the use of spinal manipulation (for acute lower back pain only), interdisciplinary rehabilitation, exercise, acupuncture, massage, yoga, cognitive behavioural therapy or relaxation. The purpose of this review was to evaluate published economic evaluations of pharmacological management for chronic lower back pain. A total of seven studies were eligible for inclusion in there view. The quality of the economic evaluations undertaken in the included studies was not high. This was primarily because of the nature of the underlying clinical evidence, most of which did not come from rigorous randomised controlled trials (RCTs), and the manner in which it was incorporated into the economic evaluations. All studies provided reasonable information about what aspects of healthcare and other resource use were identified, measured and valued.
However, the reporting of total costs was not uniform across studies. Measures of pain and disability were the most commonly collected outcomes measures. Two studies collected information on quality of life directly from participants while two studies modelled this information based on the literature. Future economic evaluations of interventions for chronic lower back pain, including pharmacological interventions, should be based on the results of well-conducted RCTs where the measurement of costs and outcomes such as quality of life and quality-adjusted lifeyears is included in the trial protocol, and which have a follow-up period sufficient to capture meaningful changes in both costs and outcomes. In the absence of RCT data, economic models should be used to estimate future costs and outcomes using robust methods.
Key Points for Decision Makers
The aim of this review was to evaluate published economic evaluations of pharmacological management for chronic lower back pain (CLBP)
The quality of the published economic evaluations was not high, primarily because of the lack of evidence from high-quality clinical trials There is a need for well-conducted randomised controlled trials of interventions for CLBP, including pharmacological interventions where the measurement of costs and outcomes such as quality of life and quality adjusted life-years is included in the trial protocol, and which have a follow-up period sufficient to capture meaningful changes in both costs and outcomes
Introduction
Lower back pain (LBP) is one of the most prevalent musculoskeletal conditions in the developed world [1] . It is likely that a majority of individuals will experience at least one bout of LBP over their lifetime, affecting both function and quality of life (QoL). Although most cases of LBP resolve within 8-12 weeks, the prevalence of chronic lower back pain (CLBP) has been reported to be between 10 and 20 % [2] . CLBP, usually defined as LBP lasting for 12 weeks or longer, accounts for the majority of physical limitation, loss of QoL and healthcare costs associated with LBP [3] .
CLBP is a common reason for medical consultations; a number of studies have estimated that the condition accounts for up to 5 % of the workload of general practitioners [4] and it is the second most common reason for visits to a physician in the USA [3] . The resultant costs of interventions can be substantial as are the indirect costs of time away from usual activities, including work [4, 5] .
Although some cases of CLBP are associated with a specific cause (e.g. radiculopathy, spinal stenosis, fracture, tumour or infection), in the majority of cases, the physiological source of patients' symptoms cannot be specified with certainty; the condition is labelled non-specific CLBP. The American College of Physicians and the American Pain Society have published a joint clinical guideline that recommends the following for the management of nonspecific CLBP [6]:
1. Provide evidence-based information on prognosis and effective self-care options, advise to remain active; 2. Consider the use of medications with proven benefits; 3. For patients with acute LBP who do not improve, consider the use of spinal manipulation; and 4. For patients who do not improve, consider the addition of interdisciplinary rehabilitation, exercise, acupuncture, massage, yoga, cognitive behavioural therapy or relaxation.
These guidelines are largely in line with other international recommendations and are the result of a substantial body of research regarding the effectiveness of interventions for CLBP [7] .
A wide variety of pharmacological treatments are used to treat CLBP; acetaminophen, non-steroidal anti-inflammatory drugs (NSAIDs), opioids, tramadol and antidepressants are recommended for use, although it is not clear that any one drug has an advantage and side effects complicate their use in the long term. A review published in 2010 recommends acetaminophen and NSAIDs as firstline options, with muscle relaxants and benzodiazepines as adjuncts, bearing in mind the high level of sedation associated with these drugs [7] .
In addition to evidence of effectiveness, information about the relative costeffectiveness of interventions is required to ensure that scarce healthcare resources are used as wisely as possible. A number of studies have reviewed the costeffectiveness of interventions for CLBP. Dagenais et al. [8] undertook a systematic review of cost-utility analyses (CUAs) of interventions for LBP, including only studies that combined CUAs with randomised controlled trials (RCTs). Of the 15 CUAs identified, 10 compared multi-modal interventions such as patient education or exercise therapy (i.e. a combination of numbers 1 and 4 in the US guideline described above), while spinal manipulation (number 3 in the US guideline), surgery and usual care from a general practitioner were evaluated by seven CUAs. In their systematic review of the cost-effectiveness of guideline-endorsed treatments for LBP, Lin et al. [9] identified 25 cost-effectiveness or cost-utility studies; 15 investigated interdisciplinary rehabilitation, exercise, acupuncture, massage, yoga, cognitive behavioural therapy or relaxation (number 4 in the US guideline), nine investigated one or more aspects of advice (evidence-based information on prognosis and effective self-care options, advise to remain active, (number 1 in the guideline) and one study investigated the costeffectiveness of spinal manipulation (number 3 in the guideline).
Neither review identified any studies that assessed the cost-effectiveness of medications used in managing LBP or CLBP. The National Institute of Health and Care Excellence (NICE) reported that no economic models could be located for NSAIDs, opioids or anti-depressants for its 2009 guideline for LBP [10] . Recently, however, two studies investigating the cost-effectiveness of duloxetine (a selective serotonin and norepinephrine reuptake inhibitor) in CLBP have been published [11, 12] , prompting renewed interest in the relative cost-effectiveness of medications for CLBP. Thus, the purpose of this review was to evaluate published economic evaluations of pharmacological management for CLBP.
Methods
A systematic search was conducted for economic evaluations (i.e. cost-minimisation, cost-effectiveness, CUA or cost-benefit analysis) of pharmacological treatments in adults with CLBP. To be included, studies had to relate the costs of a treatment to its effectiveness, for example, by reporting an incremental cost-effectiveness ratio (ICER). The following databases were searched: MEDLINE and Embase via the Ovid interface and Econlit, Psychinfo and CINAHL via the EBSCO interface using the following Medical Subject Headings terms: low back pain, drug therapy, analgesics, costs and cost analysis, cost effectiveness, cost utility, cost benefit, low back pain/dt [Drug Therapy]. The following text words were also searched for in title and abstract: low back pain, LBP, pharmaceutical*, pharmacotherap*, drug*, analgesi*, drug therap*, pain relief, medication, prescription*, pharmacolog*, over the counter, OTC, analgesic usage, prescrib*, acetaminophen, NSAID*, paracetamol, codeine, opioid*, tramadol, benzodiazepine, antiepileptic drug*, antidepressant*, cost-effectiveness, cost-utility, cost-benefit, medical cost*, health care cost*, economic evaluation. The search was limited to English language papers published between 2000 and May 2014.
The review process (screening and data extraction) was conducted by both authors, with differences or uncertainties resolved by discussion. In selecting eligible studies from the search results, titles, then abstracts and then full papers were screened (see Fig. 1 for a description of the study flow).
Data were extracted using a customised data extraction sheet and included: the type and perspective of the economic evaluation, year of valuation, country and currency of the study, patient characteristics, treatment comparators, unit costs and source of cost information, outcomes collected, whether discounting was used, the results of the economic evaluation and whether sufficient detail was provided in the manuscript to reproduce the study results. Reproducibility was judged by the authors on the basis that sufficient information was provided in the published paper such that a similar study could be designed and implemented. That is, based on the information in the manuscript, another researcher could reasonably expect to be able to undertake the same research using the same types of data and produce comparable results. The quality of the studies was also evaluated using a validated tool, the Quality of Health Economic Studies (QHES) instrument [13] . 
Results
A total of seven studies were included after screening the 101 records found in the search. Three were from the USA [12, 14, 15] , two from Canada [11, 16] , and one each from England [17] and Spain [18] . Two US papers from the same group of authors [14, 15] describe research undertaken in one private pain management practice in a nonuniversity setting; the earlier study presents the results of a non-randomised study and the latter that of the combined results of four RCTs. One Canadian study compared an implantable drug-delivery system with conventional drug therapy (14) , while a before-and-after study conducted in England [17] compared two doses of epidural steroid injections. Morrera-Domininguez et al. (2010) [18] compared the use of an anti-epileptic medication (pregabalin) with usual care (which included an analgesic other than pregabalin). Finally, Wielage and colleagues used a model originally developed by NICE to evaluate the costeffectiveness of interventions for osteoarthritis, to evaluate the costeffectiveness of duloxetine, an selective serotonin reuptake inhibitor (anti-depressant) in two settings, US private payer [15] and Quebec, Canada [11] . All studies were concerned with the treatment of CLBP; some studies focussed on patients who had experienced unsuccessful surgical intervention. Table 1 provides a summary of the information available in the selected studies and the quality of the economic evaluations undertaken.
There was some variability in terms of the sociodemographic information provided, although four of the five non-model studies reported baseline information on age, sex, duration of pain/previous surgery and employment status. Of the two modelled studies, Wielage et al. [11] reported that the age of commencement was 51 years (the average age of a CLBP patient in Canada); as is conventional in such studies, the authors included age-dependent relative risks and age-specific utility weights.
The quality of the economic evaluations undertaken in the included studies was not high. While both model studies scored highly on the QHES, the scores for the remaining studies ranged from 12/100 to 70/100. The poor quality was primarily owing to the nature of the underlying clinical evidence, in particular the use of patient subgroups, and the manner in which it was used. Four of the seven studies (4/5 non-model studies) appeared to use ''convenience'' samples, although one [15] stated that the data were obtained by combining the results of four RCTs; although the means by which the data were combined was not described. Three of the five non-model studies included sample sizes of less than 50 participants per intervention group. Given the high prevalence of CLBP, sample sizes of this size are insufficient to enable the results to be generalised beyond the study participants. Study quality was also compromised by what might be regarded as relatively ''minor issues'' such as not stating the perspective of the analysis (3/7 studies), not using discounting when appropriate (3/5 ''non-model'' studies), not discussing the choice and potential limitations of the economic analysis (5/7 studies), and not discussing potential biases in the results (4/7 studies).
All studies provided reasonable information about what aspects of healthcare and other resource use were identified, measured and valued; four of the seven publications included a table listing the resource use identified and measured and the relevant sources of value for the resources. However, the reporting of total costs was not uniform across studies.
Measures of pain and disability were the most commonly collected outcomes measures. The Oswestry Disability Index was a common measure of the latter. Two of the five non-model studies collected information on QoL directly from participants. One of these [17] used a multiattribute utility instrument, the EQ5D thus enabling the calculation of quality-adjusted life years (QALYs); the other used the SF12 but did not convert this to QALYs [18] . In the two studies that used the NICE model, QALYs were reported [11, 12] . In both studies, QALY weights (utilities) were estimated via a meta-analysis of clinical trials; pain scores were converted to utilities using a transfer-to-utilities regression equation using published sources and population-based utility weights, and adverse event weights were also derived from published sources.
While two studies reported costs and outcomes separately (i.e. cost-consequence analysis), five studies reported some form of comparison of costs and outcomes and presented results in terms of cost/QALY (i.e. an ICER). However, two of the five comparative studies did not conduct an incremental analysis. The two studies authored by Manchikanti et al. [14, 15] reported their ICERs as ''cost/1 week, cost/1 year QALY and cost/2 year QALY''. It is not clear how such results should be interpreted. Only the two model studies [11, 12] undertook sensitivity analyses. Whynes et al. [17] presented a ''modified'' sensitivity analysis of the costs of an intervention and Kumar et al. [16] presented a limited scenario analysis. Four studies [11, 12, 16, 17] were judged to be reproducible(one cost-consequence and three cost-utility studies). The QHES scores for each study are provided in ESM Appendix 1.
Discussion
Among the limited number of studies available, the duloxetine studies by Wielage and colleagues [11, 12] appear to be the highest quality, based on the strongest level The publication does not report whether these values are means or medians clinical evidence and the economic modelling. Their results suggest that when comparing the use of NSAIDs, opioids, selective serotonin-norepinephrine reuptake inhibitors and cyclo-oxygenase-2 (COX-2) inhibitors, there is evidence to support either NSAIDs/COX-2 inhibitors in post-first-line therapy; while the ICER for duloxetine would fall within the range of costeffectiveness usually considered by decision makers to be acceptable. In these studies, the use of sensitivity analyses elucidates the drivers of costeffectiveness (e.g. the probability of adverse events, the discount rate, uncertainty regarding treatment utilities). However, the absence of similarly robust clinical evidence as well as the lack of rigorous statistical and economic methods in the studies of the remaining pharmacological medications, in particular the intrathecal injections, makes it difficult to use costeffectiveness as a criterion to guide recommendations in this area.
Comparisons with intrathecal therapy are complicated by the nature of the clinical evidence available within those studies. Kumar et al. [16] found that intrathecal steroid injections dominated standard pharmacological therapy for CLBP management. However, this was a small study of only 88 patients in one centre. More informative assessments of the costeffectiveness of intrathecal therapy can only be conducted on the basis of robust clinical evidence. The clinical utility of intrathecal therapy using steroid injections in spinal stenosis has been called into question recently, potentially obviating the need for consideration of its costeffectiveness [19] . That aside, any further assessment of the costeffectiveness of intrathecal therapy must also consider whether it is a substitute for standard pharmacological medicine, or to be used after failure of such therapy. That is, would it be used at point (2) or point (3) of the American Guidelines [6] ? Clarifying its position in the treatment pathway has implications for the choice of comparator in any subsequent assessment of costeffectiveness.
In common with previous systematic reviews of the costeffectiveness of interventions for CLBP, we found that the quality of the studies, as measured by the QHES too, was mixed. In a case study of cost-effectiveness analyses in gastrointestinal reflux disease, the developers of the QHES instrument also noted a wide range of scores (43-91) with a mean of 63.6 [20] . All reviews, including ours, have identified heterogeneity in the interventions compared, the direct cost components identified and measured, the inclusion of indirect costs and the methods used to generate QALYs. Given the plethora of advice available regarding the conduct of economic evaluations, there is little excuse for authors to ignore fundamental issues such as stating the perspective of the study, transparent reporting of the types of resource use identified and sources of cost information, methods for measuring QoL outcomes and sources of QALY weights, discounting costs and benefits when the study period (including follow-up) exceeds 1 year. Poorquality research does not provide sufficient information to assist decision makers.
Conclusion
Considering the prevalence of CLBP and its implications for an individual's ability to undertake their usual activities as well as the wide range of pharmacological and nonpharmacological interventions available, clinicians and decision makers require better information about the relative cost-effectiveness of such interventions than is currently available. Future economic evaluations of interventions for CLBP, including pharmacological interventions, should be based on the results of well-conducted RCTs where the measurement of costs and outcomes such as QoL and QALYs are included in the trial protocol, and which have a follow-up period sufficient to capture meaningful changes in both costs and outcomes. In the absence of RCT data, economic models should be used to estimate future costs and outcomes using robust methods.
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